It wasn’t so long ago that I did a post explaining why after following the company for years, I finally bought a small amount of stock in the stem cell biotech, Advanced Cell Technology (ACT; symbol ACTC). In part it was motivated by my enthusiasm to see them publishing a paper, a very preliminary paper, …
Today after years of following the company Advanced Cell Technology (ACT), I finally bought stock (ACTC) in it. Why? As a stem cell researcher myself working on human ES cells, iPS cells, and many other types of stem cells, I have been following ACT for years, but have never pulled the trigger to buy their stock….until …
Why I finally bought stock in Advanced Cell Technology Read More »
Spring End Nov. 2011 Here is an updated–Who’s who in the iPS cell field? …
Some of the smartest people I have ever met in my life were scientists. But some of these same people made the dumbest mistakes I have ever seen in my life. Why? Their raw brainpower and knowledge of science is amazing, but they seemed to lack common sense and what I would call “science street …
Science street smarts: how to succeed in science in the real world Read More »
It has been a week to think about mentors and I posted somewhat autobiographically on how to find and be a good mentor a few days ago. Also along these lines, I asked one of the great mentors of all time, Irv Weissman, about his early career and who were the mentors that made the …
Who’s who in the iPS cell field? In this post, I examine the people, journals, places, funding agencies, and companies that are the leaders in the iPS cell field. I start with publishing. Last year we did a post on publishing trends in the iPS cell field. It suggested that the iPS cell field was exploding …
Who’s who in iPS cells: scientists, journals, funding agencies, countries, and biotechs Read More »
How are things looking for the stem cell field for Spring 2011? Issue One. Getting to the clinic. At this point, Geron and ACT have their FDA-approved clinical trials underway using derivatives of human embryonic stem cells. As expected no news has leaked out on how things are going and it may well be Fall …
Great ideas are the foundation of science, but funding makes great ideas become realities and a monopoly on funding hurts science. UPDATE: NIH data backs up our conclusions: overfunding wastes precious resources–give the money to smaller labs. Arguably the key driver of the exciting progress in stem cell research is funding. With the stakes so …
Stem cell monopoly: do not pass go, do not collect $200,000 Read More »